Laboratory diagnosis of TB needs to be accurate, rapid and able to provide sufficient data to start patients on proper treatment. While culture and phenotypic DST remain pillars in the diagnostic process, molecular methods have the advantage of providing key data in a very short time. Worldwide roll-out of automated platforms able to detect TB and rifampicin resistance have substantially contributed to the increase of detection and treatment of MDR-TB cases. New, more comprehensive platforms are under development or have just started commercialisation, where the main advantage will be the capacity to detect resistance to isoniazid in addition to rifampicin. Some of the platforms are designed to be placed at a more centralised and high workload level. Whole-genome sequencing (WGS) and WGS-based technologies are the promise for the future. These tests will provide a very comprehensive range of information, from extensive resistance prediction to data on transmission in the population.